M. Iavarone, M. Perrino, M. Vigano, P. Beck-peccoz, and L. Fugazzola, Sorafenib-induced destructive thyroiditis, Thyroid, vol.20, issue.9, pp.1043-1047, 2010.

L. Van-doorn, F. A. Eskens, T. J. Visser, A. Van-der-lugt, R. H. Mathijssen et al., Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma, Thyroid, vol.21, issue.2, pp.197-202, 2011.

M. Grossmann, E. Premaratne, J. Desai, and I. D. Davis, Thyrotoxicosis during sunitinib treatment for renal cell carcinoma, Clin Endocrinol (Oxf), vol.69, issue.4, pp.669-72, 2008.

I. Tamaskar, R. Bukowski, P. Elson, A. G. Ioachimescu, L. Wood et al., Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib, Ann Oncol, vol.19, issue.2, pp.265-273, 2008.

H. Miyake, T. Kurahashi, K. Yamanaka, Y. Kondo, M. Muramaki et al., Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation, Urol Oncol, vol.28, issue.5, pp.515-524, 2010.

C. Konca-degertekin, U. Coskun, B. Toruner, F. Akturk, M. Demirci et al., Hyperthyroidism and thyroid autoimmunity induced by sorafenib in metastatic renal cell cancer, Endocrine, vol.42, issue.3, pp.756-763, 2012.

T. D. Kim, M. Schwarz, H. Nogai, P. Grille, J. Westermann et al., Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosomepositive chronic myeloid leukemia, Thyroid, vol.20, issue.11, pp.1209-1223, 2010.

J. W. De-groot, B. A. Zonnenberg, J. T. Plukker, W. T. Van-der-graaf, and T. P. Links, Imatinib induces hypothyroidism in patients receiving levothyroxine, Clin Pharmacol Ther, vol.78, issue.4, pp.433-441, 2005.

J. W. De-groot, B. A. Zonnenberg, P. Q. Van-ufford-mannesse, M. M. De-vries, T. P. Links et al., A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma, J Clin Endocrinol Metab, vol.92, issue.9, pp.3466-3475, 2007.

T. Babacan, A. Sevinc, E. Akarsu, and O. Balakan, Sunitinib-induced autoimmune thyroiditis in a patient with metastatic renal cell carcinoma: a case report, Chemotherapy, vol.58, issue.2, pp.142-147, 2012.

J. Desai, L. Yassa, E. Marqusee, S. George, M. C. Frates et al., Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors, Ann Intern Med, vol.145, issue.9, pp.660-664, 2006.

B. I. Rini, I. Tamaskar, P. Shaheen, R. Salas, J. Garcia et al., Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib, J Natl Cancer Inst, vol.99, issue.1, pp.81-84, 2007.

D. Mannavola, P. Coco, G. Vannucchi, R. Bertuelli, M. Carletto et al., A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake, J Clin Endocrinol Metab, vol.92, issue.9, pp.3531-3535, 2007.

F. Illouz, S. Laboureau-soares, S. Dubois, V. Rohmer, and P. Rodien, Tyrosine kinase inhibitors and modifications of thyroid function tests: a review, Eur J Endocrinol, vol.160, issue.3, pp.331-337, 2009.

K. Ohba, T. Takayama, H. Matsunaga, A. Matsushita, S. Sasaki et al., Inappropriate elevation of serum thyrotropin levels in patients treated with axitinib, Thyroid, vol.23, issue.4, pp.443-451, 2013.

M. Daimon, T. Kato, W. Kaino, K. Takase, S. Karasawa et al., Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma, Jpn J Clin Oncol, vol.42, issue.8, pp.742-749, 2012.

S. I. Sherman, L. J. Wirth, J. P. Droz, M. Hofmann, L. Bastholt et al., Motesanib diphosphate in progressive differentiated thyroid cancer, N Engl J Med, vol.359, issue.1, pp.31-42, 2008.

M. Mohty, D. Blaise, D. Olive, and B. Gaugler, Imatinib: the narrow line between immune tolerance and activation, Trends Mol Med, vol.11, issue.9, pp.397-402, 2005.

R. Seggewiss, D. A. Price, and M. A. Purbhoo, Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update, Cytotherapy, vol.10, issue.6, pp.633-674, 2008.

B. Seliger, C. Massa, B. Rini, J. Ko, and J. Finke, Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors, Trends Mol Med, vol.16, issue.4, pp.184-92, 2010.

F. Pani, F. Atzori, G. Baghino, F. Boi, L. Tanca et al., Thyroid Dysfunction in Patients with Metastatic Carcinoma Treated with Sunitinib: Is Thyroid Autoimmunity Involved?, Thyroid, vol.25, p.11, 2015.